PT  - JOURNAL ARTICLE
AU  - Alejandra Machado
AU  - Daniel Ferreira
AU  - Michel J. Grothe
AU  - Helga Eyjolfsdottir
AU  - Per M. Almqvist
AU  - Lena Cavallin
AU  - Göran Lind
AU  - Bengt Linderoth
AU  - Åke Seiger
AU  - Stefan Teipel
AU  - Lars U. Wahlberg
AU  - Lars-Olof Wahlund
AU  - Eric Westman
AU  - Maria Eriksdotter
AU  - for the Alzheimer’s Disease Neuroimaging Initiative
TI  - The cholinergic system and treatment response in subtypes of Alzheimer’s disease
AID  - 10.1101/2020.01.23.20018507
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.01.23.20018507
4099  - http://medrxiv.org/content/early/2020/01/27/2020.01.23.20018507.short
4100  - http://medrxiv.org/content/early/2020/01/27/2020.01.23.20018507.full
AB  - BACKGROUND The heterogeneity within Alzheimer’s disease (AD) seriously challenges the development of disease modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subtypes of AD, and explored the relevance of subtype stratification in a clinical trial on encapsulated cell biodelivery (ECB) of nerve growth factor (NGF) to the basal forebrain.METHODS Structural MRI data was collected for 90 amyloid-positive patients and 69 amyloid-negative healthy controls at baseline, 6-, 12-, and 24-month follow-up. The effect of the NGF treatment was investigated in 10 biopsy verified AD patients with structural MRI data at baseline and at 6- or 12-months follow-up. Patients were classified as typical, limbic-predominant, hippocampal-sparing, or minimal atrophy AD, using a validated visual assessment method. Volumetric analyses were performed using a region-of-interest approach.RESULTS All AD subtypes showed reduced basal forebrain volume as compared with controls. Limbic-predominant subtype showed fastest basal forebrain atrophy rate, whereas minimal atrophy subtype did not show significant volume decline over time. Atrophy rates of hippocampus and precuneus also differed across subtypes. The NGF treatment seemed to slow the rate of atrophy in precuneus and hippocampus, particularly in the hippocampal-sparing AD subtype.CONCLUSIONS The cholinergic system is differentially affected in distinct atrophy subtypes of AD, possibly contributing to their differential response to cholinergic treatment. Our findings suggest that future clinical trials should target specific subtypes of AD, or at least report treatment effects stratifying by subtype.Trial registration ClinicalTrials.gov identifier: NCT01163825. Registered 14 July 2010 - https://clinicaltrials.gov/ct2/show/NCT01163825Competing Interest StatementLars Wahlberg is an owner and employee of Gloriana Therapeutics, which developed the NGF secreting device. All the other authors declared no conflicts of interest.Clinical TrialNCT01163825Funding StatementThis project is financially supported by the Swedish Foundation for Strategic Research (SSF), the Swedish Research council (VR, grant #2016-02317), the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro), the Swedish Alzheimer foundation, the Swedish Brain foundation, Åke Wiberg foundation, Åhlen foundation, King Gustaf V’s and Queen Victoria’s Foundation of Freemason, Olle Engkvist Byggmästare foundation, Ragnhild and Einar Lundström Minne, Gun and Bertil Stohnes, Sigurd och Elsa Goljes Minne, Ålderssjukdomar, Gamla Tjänarinnor, Karolinska Institutet Forskningstiftelse, Demensförbundet. We also thank Birgitta and Sten Westerberg for additional financial support. Data collection and sharing for the ADNI study was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI, National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Health-care; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immuno-therapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe ADNI dataset used and analyzed during the current study are available from the corresponding author on reasonable request. The NGF dataset generated and/or analyzed are not publicly available due to compromise of individual privacy of these patients but are available from the corresponding author on reasonable request.A βAmyloid βADAlzheimer’s diseaseADNIAlzheimer’s Diseases Neuroimaging InitiativeANOVAAnalysis of varianceAPOEApolipoprotein ECDRClinical dementia ratingChEICholinesterase inhibitorsCSFCerebrospinal fluidDARTELDiffeomorphic anatomical registration through exponentiated lie algebraDLBDementia with Lewy bodiesECBEncapsulated cell biodeliveryGCA-FGlobal cortical atrophy – FrontalGMGray matterMMSEMini-Mental State ExaminationMNIMontreal Neurological InstituteMRIMagnetic resonance imagingMTAMedial temporal atrophyNFTNeurofibrillary tangleNGFNerve growth factorNINCDS-ADRDANational Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders AssociationPAPosterior atrophyPSCPrimary somatosensory cortexROIRegion of interestSPMStatistical parametric mappingTIVTotal intracranial volumeVBMVoxel-based morphometryWMWhite matter